Vickers Vantage Corp. I
VCKAU
NASDAQ Capital Market9.60
USD
-0.71
- -
CIK
0001820190
ISIN
KYG9440B1234
Return %
Stock
S&P500
1Y
-6.16
14.68
3Y
-5.97
82.78
5Y
-5.97
70.17
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Chien-Chuen Chi
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- Keppel Bay Tower Singapore Singapore 098632
- IPO Date
- Jan 7, 2021
- CIK
- 0001820190
- Website
- vickersvantage.com
- Similar Companies
- Business
- Vickers Vantage Corp. I (VCKAU) is a blank check company, or special purpose acquisition company (SPAC), formed to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities; it currently conducts no significant operations. The company offers no core products or services beyond its SPAC structure, which provides public market access to private companies through de-SPAC transactions. Incorporated in 2020 and headquartered at 1 Harbourfront Avenue, #16-06 Keppel Bay Tower, Singapore, it targets opportunities primarily in Asia and the United States. In November 2022, Vickers Vantage Corp. I completed a reverse merger transaction through which it was acquired by Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enabling Scilex to become publicly traded under the ticker SCLX on Nasdaq; the deal followed a definitive business combination agreement signed in March 2022 valued at approximately $1.64 billion pro forma equity post-money, with Scilex equity holders rolling 100% of their interests into the combined entity. Prior to closing, the company, originally Cayman Islands-incorporated, redomesticated to Delaware and extended its business combination deadline multiple times through 2022, including shareholder approvals in June and November. The transaction provided up to $140 million in gross proceeds before expenses to support Scilex's commercialization of pain management therapies like SP-102 (SEMDEXA), clinical development programs, commercial team expansion, and business development; post-merger, Scilex leadership, headed by CEO Jaisim Shah, assumed control of the combined public entity.
Company News
Vickers Vantage Corp. I (OTCMKTS:VCKAU) Trading Down 6.9% – Here’s Why
Vickers Vantage Corp. I Announces the Separate Trading of its Common Stock and Warrants, Commencing March 3 2021
Vickers Vantage Corp. I Announces Closing of $138,000,000 Initial Public Offering
Vickers Vantage Corp. I Announces Pricing of Upsized $120,000,000 Initial Public Offering